Literature DB >> 11719277

Myotonic dystrophy--a multigene disorder.

K Larkin1, M Fardaei.   

Abstract

Myotonic dystrophy (DM1) is the most common form of adult muscular dystrophy with an estimated incidence of 1/8000 births. The mutation responsible for this condition is an expanded CTG repeat within the 3' untranslated region of the protein kinase gene DMPK. Strong nucleosome positioning signals created by this expanded repeat cause a reduction in gene expression within the region. This "field effect" is further confounded by the retention of DMPK expansion containing transcripts, which acquire a toxic gain of function. Thus, the various manifestations exhibited by DM1 patients can be explained as a result of gene silencing, nuclear retention and sequestration of nuclear factors by the CUG containing transcript.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719277     DOI: 10.1016/s0361-9230(01)00656-6

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  9 in total

1.  Hypogonadism in DM1 and its relationship to erectile dysfunction.

Authors:  Giovanni Antonini; Alessandro Clemenzi; Elisabetta Bucci; Emanuela De Marco; Stefania Morino; Antonella Di Pasquale; Pamela Latino; Gilda Ruga; Andrea Lenzi; Nicola Vanacore; Antonio F Radicioni
Journal:  J Neurol       Date:  2011-02-23       Impact factor: 4.849

Review 2.  Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.

Authors:  Laura P W Ranum; John W Day
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 3.  Myotonic dystrophy: RNA pathogenesis comes into focus.

Authors:  Laura P W Ranum; John W Day
Journal:  Am J Hum Genet       Date:  2004-04-02       Impact factor: 11.025

Review 4.  A brief history of triplet repeat diseases.

Authors:  Helen Budworth; Cynthia T McMurray
Journal:  Methods Mol Biol       Date:  2013

5.  CUGBP1 and MBNL1 preferentially bind to 3' UTRs and facilitate mRNA decay.

Authors:  Akio Masuda; Henriette Skovgaard Andersen; Thomas Koed Doktor; Takaaki Okamoto; Mikako Ito; Brage Storstein Andresen; Kinji Ohno
Journal:  Sci Rep       Date:  2012-01-04       Impact factor: 4.379

6.  Abnormal Lactate Levels Affect Motor Performance in Myotonic Dystrophy Type 1.

Authors:  Caterina Tramonti; Stefania Dalise; Federica Bertolucci; Bruno Rossi; Carmelo Chisari
Journal:  Eur J Transl Myol       Date:  2014-12-24

7.  Dosage effect of multiple genes accounts for multisystem disorder of myotonic dystrophy type 1.

Authors:  Qi Yin; Hongye Wang; Na Li; Yifu Ding; Zhenfei Xie; Lifang Jin; Yan Li; Qiong Wang; Xinyi Liu; Liuqing Xu; Qing Li; Yongjian Ma; Yanbo Cheng; Kai Wang; Cuiqing Zhong; Qian Yu; Wei Tang; Wanjin Chen; Wenjun Yang; Fan Zhang; Chen Ding; Lan Bao; Bin Zhou; Ping Hu; Jinsong Li
Journal:  Cell Res       Date:  2019-12-18       Impact factor: 25.617

8.  miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1.

Authors:  Demetris Koutalianos; Andrie Koutsoulidou; Chrystalla Mytidou; Andrea C Kakouri; Anastasis Oulas; Marios Tomazou; Tassos C Kyriakides; Marianna Prokopi; Konstantinos Kapnisis; Nikoletta Nikolenko; Chris Turner; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; George M Spyrou; Geneviève Gourdon; Eleni Zamba Papanicolaou; Grainne Gorman; Andreas Anayiotos; Hanns Lochmüller; Leonidas A Phylactou
Journal:  Mol Ther Methods Clin Dev       Date:  2021-09-14       Impact factor: 6.698

9.  Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights.

Authors:  Andrea C Kakouri; Demetris Koutalianos; Andrie Koutsoulidou; Anastasis Oulas; Marios Tomazou; Nikoletta Nikolenko; Chris Turner; Andreas Roos; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; Eleni Zamba Papanicolaou; Grainne Gorman; Hanns Lochmüller; George M Spyrou; Leonidas A Phylactou
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.